Updates in the Management of Stage III Non-Small Cell Lung Cancer (NSCLC) - Episode 5

Management of Borderline Resectable NSCLC

, , ,

The panel discusses reassessing for respectability after certain treatments.

EP. 1: Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%
EP. 2: Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC
EP. 3: Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC
EP. 4: Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC
Now Viewing
EP. 5: Management of Borderline Resectable NSCLC
EP. 6: Management of Resectable Early Stage NSCLC with Actionable Mutations
EP. 7: Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC
EP. 8: Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease
EP. 9: Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC
EP. 10: Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

Video content above is prompted by the following:

In patients deemed borderline resectable, do you re-assess for resectability after neoadjuvant chemoimmunotherapy?

  • How do you manage patients who do not undergo surgery after neoadjuvant chemoimmunotherapy?
  • How do you managepatientswho do not achieve a pCR or an MPR after neoadjuvant chemo-IO?

How do you manage patients who do not achieve a pCR or an MPR after neoadjuvant